Ulcerative Colitis

Ulcerative colitis still has its own diagnostic code, DC 7323 in 38 CFR § 4.114, but that code no longer carries its own rating table. It now reads, in full: "Rate as Crohn's disease or undifferentiated form of inflammatory bowel disease (DC 7326)." VA rewrote the entire digestive section in a final rule published March 20, 2024 (89 FR 19735) that took effect on May 19, 2024, and ulcerative colitis was one of the codes that changed the most.

If you are reading an older guide, or an older decision, you will see four tiers built on words like "moderately severe with frequent exacerbations." Those tiers are gone. The current criteria under DC 7326 turn on two things the old ones only treated as background evidence: how many episodes of diarrhea you have per day, and which class of drug it takes to control the disease. Being on a biologic or an immunosuppressant is now written into the 60 percent criteria as a requirement, not offered as circumstantial proof of severity.

That is a real change in what wins a claim. Under the old rules the fight was about the word "frequent." Under the current rules the fight is about a daily symptom count and a medication class, both of which are far easier to document if you know to document them.

This page walks through the four current tiers, what the treatment-class requirement means for a veteran who is well controlled on an expensive drug, why the anti-pyramiding rules in 38 CFR § 4.113 and § 4.114 push colitis toward a single predominant digestive evaluation, the C&P and laboratory evidence that moves a tier, and the secondary chains colitis opens up, including inflammatory arthritis, colorectal-cancer surveillance, and surgical residuals after colectomy.

TL;DR

• Ulcerative colitis is coded at 38 CFR § 4.114, DC 7323, which now says only "Rate as Crohn's disease or undifferentiated form of inflammatory bowel disease (DC 7326)." The change took effect May 19, 2024.
• The four current tiers turn on daily diarrhea episodes, the class of medication controlling the disease, and signs of systemic toxicity. 100% requires severe disease unresponsive to treatment plus hospitalization at least once a year plus either an inability to work or recurrent abdominal pain with at least two listed severe findings; 60% requires management with immunosuppressants or biologics plus four to five daily episodes of diarrhea plus intermittent toxicity signs; 30% is oral and topical agents with three or fewer daily episodes and minimal toxicity signs; 10% is the same picture with no signs of systemic toxicity.
• The treatment class is now a criterion, not just evidence. The line between 30% and 60% is drawn largely by whether the disease is controlled on immunosuppressants or biologics rather than on oral and topical agents.
• The old attack-frequency language ("moderate with infrequent exacerbations," "pronounced," "liver abscess") is superseded. If a current decision applies it to a period after May 19, 2024, that is an error worth appealing.
• Note (2) to DC 7326 requires the diagnosis to be confirmed by endoscopy or radiologic studies. A colitis claim resting on symptom reports alone has a documentation problem before it reaches the tiers.
• Under § 4.113 and § 4.114, ulcerative colitis is generally rated as a single predominant digestive evaluation rather than stacked with other coexisting GI diagnostic codes.
• Secondary chains under 38 CFR § 3.310 include inflammatory arthritis, increased colorectal-cancer risk and surveillance, and surgical residuals after colectomy. Note (1) directs that after colectomy or colostomy with persistent or recurrent symptoms, VA rates under DC 7326 or DC 7329, whichever pays more.
• A C&P exam that captures only "stable on medication today" without the daily episode count and the medication class almost always rates to the floor.
• In Claim Raven's analysis of 389 BVA ulcerative colitis cases, 39.1% were remanded, 22.6% granted, and 38.3% denied. Of the 306 cases with a C&P adequacy determination, 59.8% had the exam flagged as inadequate.

DC 7323 Sends You to DC 7326

Ulcerative colitis lives at DC 7323 in the digestive section of 38 CFR § 4.114, and the entry there is one sentence long:

7323 Colitis, ulcerative: Rate as Crohn's disease or undifferentiated form of inflammatory bowel disease (DC 7326).

So the code on your rating decision may still read 7323, but the criteria being applied are the DC 7326 criteria. Here is that regulatory text in full:

Severe inflammatory bowel disease that is unresponsive to treatment; and requires hospitalization at least once per year; and results in either an inability to work or is characterized by recurrent abdominal pain associated with at least two of the following: (1) six or more episodes per day of diarrhea, (2) six or more episodes per day of rectal bleeding, (3) recurrent episodes of rectal incontinence, or (4) recurrent abdominal distension, 100% Moderate inflammatory bowel disease that is managed on an outpatient basis with immunosuppressants or other biologic agents; and is characterized by recurrent abdominal pain, four to five daily episodes of diarrhea; and intermittent signs of toxicity such as fever, tachycardia, or anemia, 60% Mild to moderate inflammatory bowel disease that is managed with oral and topical agents (other than immunosuppressants or other biologic agents); and is characterized by recurrent abdominal pain with three or less daily episodes of diarrhea and minimal signs of toxicity such as fever, tachycardia, or anemia, 30% Minimal to mild symptomatic inflammatory bowel disease that is managed with oral or topical agents (other than immunosuppressants or other biologic agents); and is characterized by recurrent abdominal pain with three or less daily episodes of diarrhea and no signs of systemic toxicity, 10%

Read the conjunctions, because they are doing most of the work. Each tier is a list of requirements joined by "and," not a menu. The 60 percent tier is not "biologics or four to five episodes of diarrhea." It is the medication class and the episode count and the intermittent toxicity signs.

The 10 and 30 percent tiers are nearly identical sentences. Both describe disease managed with oral or topical agents and three or fewer daily episodes of diarrhea. The only thing separating them is whether there are "minimal signs of toxicity such as fever, tachycardia, or anemia" or "no signs of systemic toxicity." That means a single documented low hemoglobin, a recorded fever during a flare, or a resting tachycardia is the difference between 10 and 30 percent. Those are things a primary care note captures routinely and a rating decision misses routinely.

The 60 percent tier is where the 2024 rewrite changed the most. The medication class is now a criterion. Management "on an outpatient basis with immunosuppressants or other biologic agents" is a requirement of the tier, so a veteran on infliximab, vedolizumab, adalimumab, azathioprine, or a similar agent has already satisfied one of the three elements by virtue of the prescription. That is the single most useful fact on this page. Under the old criteria being on a biologic was circumstantial evidence that a rater could discount. Now it is an element.

There is a trap inside that same change. A biologic can control the disease well. A veteran who is on a biologic and, because it is working, has fewer than four daily episodes of diarrhea and no toxicity signs does not meet the 60 percent tier as written. The drug that helps is also the drug that makes the symptom count fall below the threshold. That tension is real and it is not resolved by the regulation.

The 100 percent tier requires disease that is "unresponsive to treatment," annual hospitalization, and then either an inability to work or two of the four listed severe findings. Three separate elements, all required. It describes disease that treatment has failed to control, which is why a veteran who is severely ill but stable on aggressive therapy generally lands at 60 rather than 100.

Two notes attached to DC 7326 matter for a claim. Note (2) requires VA to confirm the diagnosis by endoscopy or radiologic studies, so the colonoscopy and biopsy report are not optional supporting documents, they are the predicate. Note (1) covers what happens after surgery: following colectomy or colostomy with persistent or recurrent symptoms, VA rates under DC 7326 or DC 7329 (resection of the large intestine), whichever provides the higher rating.

If your claim was already pending on May 19, 2024, both versions of the criteria are potentially in play across different periods of the claim. That is covered under effective dates below.

The Rating Driver Is a Daily Count and a Drug Class

The single most useful thing to understand about the current criteria is that they ask for numbers a veteran can actually produce: episodes of diarrhea per day, the name of the drug controlling the disease, and whether fever, tachycardia, or anemia show up in the record.

That is a problem for how C&P exams are usually built. The exam captures one day. If the day of the exam falls during a remission, and the examiner records "patient currently stable on medication, no acute distress," that note is accurate and also nearly useless. It documents the diagnosis and the present moment. It does not establish the typical daily episode count, and it may not even record which medication class is in use.

The objective signals that actually separate the tiers are:

• Daily episodes of diarrhea. This is now the central number. Three or fewer puts you in the 10 or 30 percent band, four to five is the 60 percent band, and six or more is one of the findings the 100 percent tier counts. A contemporaneous symptom log covering good weeks and bad ones is worth more here than any narrative statement, because the criteria are written in daily counts and a log is the only thing that produces one.
• Medication class, named specifically. The regulation splits on "immunosuppressants or other biologic agents" versus "oral and topical agents (other than immunosuppressants or other biologic agents)." Mesalamine is an oral or topical agent. Infliximab, adalimumab, vedolizumab, and azathioprine are not. Make sure the record names the drug, because the tier turns on which side of that line it falls.
• Signs of toxicity: fever, tachycardia, anemia. These three are named at 30 and 60 percent and they are the only thing separating 10 from 30. A complete blood count showing low hemoglobin, or vitals showing fever or a fast resting heart rate during a flare, is the cheapest evidence on this list and the most often missing.
• Hospitalization within the past year. Required for the 100 percent tier. Admissions for a flare, dehydration, or a complication should be identified by date in the claim.
• Unresponsiveness to treatment. Also required at 100 percent, and it is a distinct point from severity. The record has to show the disease persisting despite treatment, not merely that the disease is bad.
• Endoscopy or radiologic confirmation. Note (2) requires it for a DC 7326 diagnosis. Attach the colonoscopy and pathology reports.

Weight loss, albumin, and general debility still matter clinically, and they still support a picture of severe disease, but they are no longer the named criteria they were before May 2024. If you are building a claim off an older guide that tells you to lead with the weight trend and the malnutrition finding, you are documenting the superseded standard.

When a claim is built on the diagnosis plus a single remission-day exam, it rates to the floor. When it is built on a daily symptom log, a named medication, and labs or vitals showing toxicity signs, the higher tiers become defensible.

C&P Exam Mechanics: What the Examiner Has to Capture

The intestinal-conditions DBQ for ulcerative colitis is built to capture exactly the systemic picture the tiers require. The problem in the dataset is not the form. It is how often the form gets filled in for the day of the exam rather than the disease over time.

A C&P examination that supports an accurate tier should record:

• The diagnosis and method of confirmation (colonoscopy, biopsy, imaging), which Note (2) requires.
• The typical number of daily episodes of diarrhea, and whether that number changes between flare and remission.
• The current medication by name and class, specifically whether it is an immunosuppressant or biologic agent or an oral or topical agent.
• Any signs of toxicity: fever, tachycardia, or anemia, with the supporting vitals and labs.
• Whether and how often the condition requires hospitalization, with dates.
• Whether the disease has responded to treatment or persisted despite it.
• Rectal bleeding episodes, rectal incontinence, and abdominal distension, which are the named findings at the 100 percent tier.
• Functional impact on daily activities and work, including any inability to work.

The recurring failure is the remission-day exam. The examiner sees a veteran who is currently controlled, writes that down accurately, and the daily episode count during flares, the medication class, and the labs never make it into the report. The rater then rates off what is in front of them, which is a controlled patient, and assigns 10 percent.

This is the cleanest read I have on why the inadequate-exam rate in this subset is what it is. In Claim Raven's analysis of the 306 ulcerative colitis cases that had a C&P adequacy determination, 59.8% had the exam flagged as inadequate. A colitis exam that does not develop the daily episode count, the medication class, and the laboratory markers is rating a chronic relapsing disease off a single calm day, and the Board notices. Note that this figure is drawn from cases decided largely under the pre-2024 criteria; whether the more concrete current criteria reduce the inadequate-exam rate is a question the data cannot answer yet.

Anti-Pyramiding: One Predominant Digestive Evaluation

The digestive section has its own anti-pyramiding logic in 38 CFR § 4.113 and § 4.114, and it cuts the opposite way from the knee.

Section 4.113 recognizes that coexisting abdominal and gastrointestinal conditions often produce overlapping symptom pictures, so the same disability cannot be evaluated under several diagnostic codes at once. Section 4.114 then lists a set of digestive diagnostic codes, DC 7323 among them, that are not to be combined with each other. Instead, a single evaluation is assigned under the diagnostic code that reflects the predominant disability picture, with elevation to the next higher level only where the severity warrants it.

For ulcerative colitis, the practical consequence is the inverse of the knee stacking strategy. You generally do not get DC 7323 plus a separate rating for an overlapping GI code such as irritable bowel syndrome or another listed digestive condition layered on top, because the regulation treats them as one digestive disability rated under the predominant code. The argument that actually moves a colitis rating is not "add another code." It is "rate the predominant code at the correct, higher tier."

That changes where the effort goes. The fight in a colitis claim is vertical, pushing the evaluation from 10 to 30, or 30 to 60, on the daily episode count, the medication class, and the toxicity signs, rather than horizontal stacking across codes. The exceptions are conditions that are genuinely separate disabilities rather than overlapping GI symptoms, which is where the secondary chains below come in.

Secondary Chains: What Colitis Opens Up

Under 38 CFR § 3.310, secondary service connection can be granted for a condition caused by, or aggravated by (Allen v. Brown), a service-connected condition. Ulcerative colitis is a systemic inflammatory disease, and several of its downstream conditions are distinct disabilities rated under their own codes, which keeps them outside the § 4.114 anti-pyramiding bar.

Inflammatory arthritis. Inflammatory bowel disease is associated with extra-intestinal arthritis and related spondyloarthropathy. When a veteran develops an inflammatory joint condition with a documented nexus to service-connected colitis, that arthritis is a separate disability rated under the musculoskeletal codes, not folded into the digestive evaluation.

Anemia. Anemia is named in the current criteria as one of the "signs of toxicity" at both 30 and 60 percent, so within the colitis rating it functions as tier evidence rather than a separate code. That makes it more valuable than it was under the old criteria, not less: a documented low hemoglobin is one of the three findings that lifts a claim off the 10 percent floor. The labs documenting it belong in the file either way.

Colorectal-cancer risk and surveillance. Long-standing ulcerative colitis carries an increased risk of colorectal cancer, which is why surveillance colonoscopy is part of standard management. The surveillance itself is not a ratable disability, but the elevated risk is a documented feature of the disease, and a colorectal cancer that develops with a nexus to service-connected colitis is its own claim under the appropriate digestive or neoplasm code.

Surgical residuals after colectomy. Severe ulcerative colitis can lead to colectomy, sometimes with a permanent ostomy. Note (1) to DC 7326 governs here: following colectomy or colostomy with persistent or recurrent symptoms, VA rates under either DC 7326 or DC 7329 (resection of the large intestine), whichever provides the higher rating. Run both and take the better one, because nothing in the process does that comparison for you automatically. Impairment of sphincter control is separately rated under DC 7332. Colectomy is also strong retrospective evidence of how severe the underlying disease was, which matters for the period before surgery.

For any of these chains, the nexus opinion has to identify the mechanism, address the time course, and rule out other causes. A bare "this is secondary to colitis" without rationale is not probative. A factually grounded, fully reasoned opinion carries the case.

Effective Dates and the Disease Course Over Time

Ulcerative colitis is a relapsing, remitting disease, and the rating can and should change as the disease course changes. Three timing issues recur.

The first is the in-service onset. A veteran who had the first flares, the first scope, or the first GI workup during service has a service-connection and effective-date argument anchored to that period. If the service treatment records are thin on the GI complaints, the effective date can default to the date of claim rather than the date the disease actually manifested, which can cost years of back pay. Buddy statements and any contemporaneous documentation help fill that gap.

The second is the staged rating. Because severity moves, a single flat rating across years often does not match the record. A stretch with four to five daily episodes of diarrhea, immunosuppressant or biologic therapy, and documented fever, tachycardia, or anemia may support 60 percent for that period even if the veteran is better controlled later. The medical record, read chronologically, supports staged evaluations that track the disease, and a claim that ignores the worst stretches understates the rating for those periods.

The third is the criteria change itself. The amended digestive criteria took effect May 19, 2024. For a claim already pending on that date, the general rule is that the old criteria apply to the period before the effective date and the amended criteria apply from the effective date forward, with VA considering both and staging the rating where the evidence supports different levels in different periods. Amended criteria are not applied retroactively to a period before their effective date. If a decision on your claim applied the old attack-frequency language to a period after May 19, 2024, or applied the current criteria to a period before it, that is a specific, checkable error to raise on appeal.

Common Evidence Gaps in Ulcerative Colitis Claims

A few patterns I have noticed across BVA decisions involving ulcerative colitis. These decisions were largely made under the pre-2024 criteria, so I have noted where the current criteria change what you should document.

The remission-day exam. The most common gap, by a wide margin. The C&P exam captures a controlled day, the examiner accurately records a stable patient, and the typical symptom burden never enters the record. The rating defaults to 10 percent because that is all the exam documents. This gap did not go away with the 2024 rewrite. It just changed shape: what is missing now is the typical daily episode count rather than the annual flare history.

No daily episode count. Under the old criteria the missing number was attacks per year. Under the current criteria it is episodes of diarrhea per day, and it matters more, because the tiers are written directly in those numbers: three or fewer, four to five, six or more. When the record contains no count, the rater has nothing to place the claim above the floor with. The veteran's own symptom log is often the only source that fills this in, and it should cover both good stretches and flares so the typical picture is visible.

Missing toxicity signs. Fever, tachycardia, and anemia are the named "signs of toxicity" in the current criteria, and their presence or absence is the only thing separating 10 percent from 30 percent. A CBC showing low hemoglobin, or vitals recorded during a flare, frequently are not pulled into the rating analysis even when they sit in the treatment records. This is the cheapest evidence available on a colitis claim and the most commonly left out.

Medication class not identified. This is the gap the 2024 rewrite made most costly. Management with immunosuppressants or biologic agents is now an element of the 60 percent tier, not merely persuasive evidence, so a record that lists "medication: as prescribed" or names a drug without identifying its class leaves an element unproven. Name the drug, state its class, and cite the prescription date range.

Flattening into one calm rating. Because severity fluctuates, a claim that asks for a single rating across a multi-year period tends to be set at the controlled baseline, leaving the worst stretches under-rated. Staged ratings that track the documented disease course are often the more accurate read of the file.

I do not know exactly what share of ulcerative colitis claims have one or more of these gaps. What I can say from Claim Raven's analysis of 389 BVA ulcerative colitis cases is that 59.8% of the 306 cases with a C&P adequacy determination had the exam flagged as inadequate, and remands ran at 39.1%, the largest single share of any outcome in this subset. That pattern is consistent with the evidence-gap dynamics in this post. The Board is sending colitis cases back for more development more often than it is granting or denying them outright, which is what you would expect when the exams capture the diagnosis but not the disease activity the tiers actually measure. Grants ran at 22.6% and denials at 38.3%.

Bottom Line

Ulcerative colitis is coded at DC 7323, which since May 19, 2024 directs VA to rate it under the DC 7326 criteria. Those four tiers are defined by three things: the number of daily episodes of diarrhea, whether the disease is controlled by an immunosuppressant or biologic rather than an oral or topical agent, and whether fever, tachycardia, or anemia appear in the record. The diagnosis gets you in the door at 10 percent, and it has to be confirmed by endoscopy or imaging to get that far. Everything above the floor is an evidence problem, but it is a more tractable one than it used to be, because the current criteria ask for countable facts instead of adjectives like "frequent" and "pronounced." The claims that rate accurately are built on a daily symptom log, a named medication, and labs or vitals showing toxicity signs, not on a single remission-day exam that records a stable patient and nothing else. Unlike a joint condition, the strategy is vertical, not horizontal: under § 4.113 and § 4.114 you rate the predominant digestive code at the correct higher tier rather than stacking codes, while genuinely separate disabilities like inflammatory arthritis or colectomy residuals get their own ratings through the secondary chains. Same diagnosis, different paper trail, different outcome.

Related Conditions

Ulcerative colitis shares rating logic and proof problems with the other digestive pages, because the same documentation issues repeat across GI claims. Veterans dealing with overlapping symptoms or unsure which code predominates should review IBS, GERD, diverticulitis, and hemorrhoids, then use the secondary conditions tool to map out inflammatory arthritis, anemia, and surgical residuals before assuming a single digestive rating tells the whole story.

Methodology and Limitations

• Data source: Rating criteria quoted from the current 38 CFR § 4.114, where DC 7323 (Colitis, ulcerative) directs "Rate as Crohn's disease or undifferentiated form of inflammatory bowel disease (DC 7326)," so the tier text is DC 7326's. Sphincter-control residuals under DC 7332 and large-intestine resection under DC 7329. The governing amendment is the final rule "Schedule for Rating Disabilities: The Digestive System," 89 FR 19735, published March 20, 2024, effective May 19, 2024. Anti-pyramiding and predominant-disability rules from § 4.113 and § 4.114. Secondary service connection from § 3.310. Case law from Allen v. Brown on secondary aggravation.
• Sample size: Patterns in this post are drawn from Claim Raven's analysis of 101,518 condition records drawn from the analyzed subset of Claim Raven's 501,000+ Board-decision library, including 389 ulcerative colitis cases. Within that subset, outcomes ran 39.1% remanded, 22.6% granted, and 38.3% denied. Of the 306 cases that carried a C&P adequacy determination, 59.8% had the examination flagged as inadequate. The dataset captures overall outcome rather than a per-tier breakdown across the four levels.
• Classification approach: Tier definitions drawn from the current regulatory text of DC 7326, which DC 7323 incorporates by reference. Anti-pyramiding analysis follows § 4.113 and § 4.114. Secondary-connection analysis follows § 3.310 and Allen v. Brown.
• Limitations:
• The BVA cases predate the criteria in this post. The 389 decisions were largely decided under the pre-May-2024 attack-frequency tiers. The outcome and exam-adequacy rates describe how the Board handled the old standard. They should not be read as a forecast of how claims rate under DC 7326.
• The current tiers are more concrete than the ones they replaced, but they are not fully determinate. "Minimal signs of toxicity" versus "no signs of systemic toxicity" is the line between 10 and 30 percent and is not numerically defined, so application still varies at the RO level.
• The treatment-class criterion cuts both ways. A biologic that controls the disease can push the daily episode count below the 60 percent threshold, and the regulation does not address that tension.
• Anemia appears inside the 30, 60, and 100 percent criteria as a severity indicator rather than a separately rated code.
• Because severity fluctuates, staged ratings are common, and any single flat rating across a multi-year period may not match the disease course.
• Selection bias: BVA-level patterns reflect cases that appealed. Most ulcerative colitis claims resolve at the RO level and are not in any BVA dataset.
• These observations reflect patterns from the regulatory text, case law, and BVA decisions. They are not predictions of individual outcomes.